

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/595,909
	Filing Date	To be assigned
	First Named Inventor	Petra Schrotz-King
	Art Unit	1645
(Multiple sheets used when necessary)	Examiner	Nina ARCHIE
SHEET 1 OF 3	Attorney Docket No.	0088562-015US0

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	A1	58767	10-16-1866	Broughton, John	
	A2	4376110	03-08-1983	David, et al.	
	A3	4486530	12-04-1984	David, et al.	
	A4	4493795	01-15-1985	Nestor, Jr. et al.	
	A5	4769330	09-06-1988	Paoletti, et al.	
	A6	4881175	11-14-1989	Ladner, Robert	
	A7	5013653	05-07-1991	Huston, et al.	
	A8	5017487	05-21-1991	Stunnenberg, et al.	
	A9	5091513	02-25-1992	Huston, et al.	
	A10	5132405	07-21-1992	Huston, et al.	
	A11	5258498	11-02-1993	Huston, et al.	
	A12	5260203	11-09-1993	Ladner, et al.	
	A13	5455030	10-03-1995	Ladner, et al.	
	A14	5470958	11-28-1995	Blaser, et al.	
	A15	5476786	12-19-1995	Huston, James S.	
	A16	5482858	01-09-1996	Huston, et al.	
	A17	5554372	09-10-1996	Hunter, Robert L.	
	A18	07/779,499	10-18-1991	Daynes, Raymond A.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document <i>Country Code-Number-Kind Code</i> Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	B1	GB 2188638A	10-07-1987	Winter, Gregory Paul		
	B2	WO 1989/001973	03-09-1989	Applied Biotechnology, Inc.		
	B3	WO 1989/007136	08-10-1989	Whitehead Institute for Biomedical Research		
	B4	WO 1990/007936	07-26-1990	Chiron Corporation		
	B5	WO 1990/011092	10-04-1990	Vical, Inc.		
	B6	WO 1991/000906	01-24-1991	Genetics Institute, Inc.		
	B7	WO 1991/002805	03-07-1991	Viagenc, Inc.		

Examiner Signature	/Nina Archie/	Date Considered	12/19/2011
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/595,909
	Filing Date	To be assigned
	First Named Inventor	Petra Schrotz-King
	Art Unit	1645
(Multiple sheets used when necessary)	Examiner	Nina ARCHIE
SHEET 2 OF 3	Attorney Docket No.	0088562-015US0

B8	WO 1991/010741	07-25-1991	Cell Genesys, Inc.		
B9	WO 1992/003917	03-19-1992	Genpharm International, Inc.		
B10	WO 1992/003918	03-19-1992	Genpharm International, Inc.		
B11	WO 1993/003709	03-04-1993	Vical, Inc.		
B12	WO 1993/025234	12-23-1993	The Regents of the University of California		
B13	WO 1993/025698	12-23-1993	The United States Government as represented by The Secretary of the Department of Health and Human Services		
B14	WO 1994/003622	02-17-1994	Imperial College of Science, Technology and Medicine		
B15	WO 1994/009131	04-28-1994	Scotgen Limited		
B16	WO 1994/013804	06-23-1994	Cambridge Antibody Technology Limited		
B17	WO 1994/013806	06-23-1994	The Dow Chemical Company		
B18	WO 1997/028816	08-14-1997	Ludwig Institute for Cancer Research		
B19	WO 1999/049026	09-30-1999	Peptide Therapeutics Limited		
B20	WO 2002/100348	12-19-2002	Genmab A/S		
B21	WO 2003/017935	03-06-2003	Genmab A/S		
B22	WO 2003/022307	03-20-2003	Acambis Research Limited		
B23	WO 2003/091561	11-06-2003	Robert Bosch GMBH		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
C1	ANDERSEN et al. 1999.	"An assay for peptide binding to HLA-Cw*0102." Tissue Antigens 54: 185-190.	
C2	ANG, et al. 2001.	"Guillain-Barre' Syndrome- and Miller Fisher Syndrome-Associated <i>Campylobacter jejuni</i> Lipopolysaccharides Induce Anti-GM1 and Anti-GQ1b Antibodies in Rabbits." Infection and Immunity 69(4):2462-2469.	
C3	COTTON, et al. 1992.	"High-efficiency receptor-mediated delivery of small and large (48kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles." Proc. Natl. Acad. Sci. USA 89:6094-6098.	
C4	COX and Coulter, 1997.	"Adjuvants-a classification and review of their modes of action." Vaccine, 15(3):246-256.	
C5	DEBERNARDI, et al. 1992.	"Inhibition of cAMP accumulation by intracellular calcium mobilization in C6-2B cells stably transfected with substance K receptor cDNA." Proc Natl Acad Sci USA 88:9257-9261.	
C6	DONNELLY, et al. 1997.	"DNA Vaccines." Annu Rev Immunol 15:617-648.	

Examiner Signature	/Nina Archie/	Date Considered	12/19/2011
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/595,909
	Filing Date	To be assigned
	First Named Inventor	Petra Schrotz-King
	Art Unit	1645
(Multiple sheets used when necessary)	Examiner	Nina ARCHIE
SHEET 3 OF 3	Attorney Docket No.	0088562-015US0

C7	FELGNER, et al. 1987. "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure." Proc. Natl. Acad. Sci. USA 84:7413-7417.	
C8	KOLLS, et al. 1994. "Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer." Proc. Natl. Acad. Sci. USA 91:215-219.	
C9	KOTIN, et al. 1990. "Site-specific integration by adeno-associated virus." Proc Natl Acad Sci USA 87:2211-2215.	
C10	MAKINO, et al. 2001. "Genetically modified Shiga toxin 2c (Stx2c) producing <i>Escherichia coli</i> is a vaccine candidate for porcine edema disease." Microbial Pathogenesis 31:1-8.	
C11	REES, et al. 1995. "Campylobacter Jejuni Infection and Guillain-Barré Syndrome." New England Journal of Medicine 333(21):1374-1379.	
C12	SMITH, et al. 1999. "Quinolone Resistant <i>Campylobacter Jejuni</i> Infections in Minnesota, 1992-1998." New England Journal of Medicine 340(20): 1525-1532.	
C13	TURNER, et al. 2001. "Construction and Characterization of Genetically Defined <i>aro omp</i> Mutants of Enterotoxigenic <i>Escherichia coli</i> and Preliminary Studies of Safety and Immunogenicity in Humans" Infection and Immunity 69(8): 4969-4979.	
C14	VINCENT, et al. 1993. "Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene." Nature Genetics 5:130-134.	
C15	WANG, et al. 1987. "pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse" Proc. Natl. Acad. Sci. USA 84:7851-7855.	
C16	WU, et al. 1989. "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements <i>in Vivo</i> ." Journal of Biological Chemistry 264(29):16985-16987.	

Examiner Signature	/Nina Archie/	Date Considered	12/19/2011
<p>*<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.  
DWT 14861803v1 09/25/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./